OverviewSuggest Edit

Imcyse is a developer of active specific immunotherapies for the treatment and prevention of severe chronic diseases caused by disruptions of the immune system. Its active immunotherapy technology platform allows it to destroy locally the immune cells involved in the destruction of the diseased organ.


Latest Updates

Employees (est.) (Nov 2019)31

Key People/Management at Imcyse

Pierre Vandepapeliere

Pierre Vandepapeliere

Thomas Taapken

Thomas Taapken

Executive Chairman
Marcelle van Mechelen

Marcelle van Mechelen

Senior Scientific Advisor
Geoffrey Gloire

Geoffrey Gloire

IP Director
Yves Lobet

Yves Lobet

Portfolio Director
Jean van Rampelbergh

Jean van Rampelbergh

Clinical Director
Show more

Imcyse Financials and Metrics

Summary Metrics

Founding Date


Imcyse total Funding

$46.6 m

Imcyse latest funding size

$39.18 m

Time since last funding

5 months ago

Imcyse investors

Imcyse's latest funding round in June 2019 was reported to be $39.2 m. In total, Imcyse has raised $46.6 m
Show all financial metrics

Imcyse Online and Social Media Presence

Embed Graph

Imcyse Frequently Asked Questions

  • When was Imcyse founded?

    Imcyse was founded in 2010.

  • Who are Imcyse key executives?

    Imcyse's key executives are Pierre Vandepapeliere, Thomas Taapken and Marcelle van Mechelen.

  • How many employees does Imcyse have?

    Imcyse has 31 employees.

  • Who are Imcyse competitors?

    Competitors of Imcyse include Atara Biotherapeutics, NeuralStem and Keros Therapeutics.